nitroxoline | 5-NOC tablets coated. 50 mg 50 pcs.

Latin name

5-NOK

Release form

film-coated tablets.

Packing

50 pcs

Pharmacological action of

Pharmacodynamics

Antimicrobial drug derived from 8-hydroxyquinoline. It has a wide spectrum of action. Selectively inhibits the synthesis of bacterial DNA, forms complexes with metal-containing enzymes of the microbial cell.

Active against:

Gram-positive bacteria: Staphylococcus spp. (including Staphylococcus aureus) Streptococcus spp., including: Beta-hemolytic Streptococcus Streptococcus pneumoniae Enterococcus faecalis Corynebacterium spp Bacillus subtilis.

Gram-negative bacteria: Escherichia coli Proteus spp Klebsiella spp Salmonella spp Shigella spp Enterobacter spp Haemophilus influenzae Neisseria gonorrhoeae.

Other microorganisms: Ureaplasma urealyticum Mycoplasma hominis Mycobacterium tuberculosis Trichomonas vaginalis.

Some types of fungi: candida, dermatophytes, mold fungi, some pathogens of deep mycoses.

Pharmacokinetics

Absorption

Nitroxoline is well absorbed from the gastrointestinal tract (90%). Cmax in plasma is achieved 1.5-2 hours after ingestion.

Metabolism and excretion

Metabolized in the liver. It is excreted mainly by the kidneys unchanged and partially with bile. There is a high concentration of conjugated and unconjugated drug in the urine.

Contraindications

Cataract

severe renal failure (CC less than 20 ml / min)

severe liver failure

children under 3 years of age

pregnancy

lactation (increased sensitivity srdlk other sensitivity to other quinolines.

Use during pregnancy and lactation

Contraindicated in pregnancy and lactation (breastfeeding).

Composition

1 coated tablet contains:

Active ingredient: nitroxoline - 50 mg.

Excipients: calcium hydrogen phosphate, lactose monohydrate, corn starch, colloidal silicon dioxide, povidone K25, purified talc, crospovidone, magnesium stearate.

Shell composition: acacia gum, sodium carmellose, povidone K25, sucrose, colloidal silicon dioxide, purified talc, corn starch, calcium carbonate, titanium dioxide, sunset yellow dye E110, yellow quinoline dye E104.

Dosage and administration of

For adults and adolescents: the standard dose is 400 mg / day, divided into 4 doses (2 tablets 4 times / day). The maximum dose is 800 mg / day.

Children older than 5 years: average dose - 200-400 mg / day, divided into 4 doses.

Children 3-5 years of age: average dose - 200 mg / day, divided into 4 doses.

The course of treatment is 2-4 weeks, if necessary, therapy is continued in intermittent courses (2 weeks for a month). Tablets should be taken before meals.

Use in case of impaired liver function

Patients with liver failure are recommended to use half the standard daily dose of the drug - 200 mg / (1 tablet 4 times / day).

Use in cases of impaired renal function

Patients with moderate renal insufficiency (CC more than 20 ml / min) are recommended to use half the standard daily dose of the drug - 200 mg / (1 tablet 4 times / day).

Side effects of the

From the digestive system: nausea, vomiting (can be prevented by taking the drug with food), increased activity of hepatic transaminases.

From the side of the central nervous system and peripheral nervous system: ataxia, headache, paresthesia, polyneuropathy.

From the cardiovascular system: tachycardia.

Allergic reactions: skin rash.

Other: thrombocytopenia, increased serum uric acid level.

Drug Interaction

Not described.

Overdose

There are no data on overdose or clinical signs of nitroxoline poisoning.

Storage conditions

Store at a temperature not exceeding 25 РC.

Keep out of the reach of children.

Expiration

5 years.

Deystvuyuschee substances

nitroxoline

Pharmacy

pharmacy terms

dosage form

drug vein form

tablets

Sandoz, Switzerland